Reuters - Biogen and partner Eisai Co Ltd are ending two late-stage trials for t...
Reuters - Biogen and partner Eisai Co Ltd are ending two late-stage trials for the experimental Alzheimer’s drug aducanumab, in a setback to efforts to find treatments for the disease and for Biogen’s stock, which lost more than $17 billion of its value on Thursday.
Investors believe the successful development of a treatment for Alzheimer’s, which affects about 5.7 million Americans, will result in multi-billion dollar annual sales. Still-experimental treatments have had a dismal track record, with more than 100 failures. The trials ended just two weeks after Eisai’s chief executive had expressed confidence in the drug. “I believe we have already gone through the riskiest stage,” Haruo Naito had said at a news briefing earlier this month.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Biogen scraps Alzheimer drug trials, shares slump by a quarterBiogen and partner Eisai Co Ltd are ending two late-stage trials testing the exp...
Weiterlesen »
Biogen heads for the worst day in a decade after ending trial for blockbuster Alzheimer's drugShares of Biogen plummeted Thursday after the company halted the trial of Alzheimer's disease drug aducanumab.
Weiterlesen »
Biogen shares plunge more than 25% after ending trial for Alzheimer's drug Aducanumab
Weiterlesen »
Biogen's stock plummets after phase 3 trial of Alzheimer's treatment discontinuedShares of Biogen Inc. plummeted 26% toward a near 3-year low in premarket trade Thursday, after the biotechnology company and Japan's Eisai Co. Ltd. said...
Weiterlesen »
Biogen stock plummets 28% after halting Alzheimer’s trialsShares of pharmaceutical giant Biogen Inc. plunged 28% on Thursday morning after the drugmaker said it would discontinue its Phase 3 trials of aducanumab, an...
Weiterlesen »
Biogen loses same Alzheimer’s bet others have lostThe failures of similar drugs in formal trials meant Biogen’s effort was always a long shot. Yet ditching it vaporized $18 bln, or over a quarter, of the biotech’s value. The giant market for a therapy and the fear of missing out lured in both the company and Wall Street.
Weiterlesen »
Stocks making the biggest moves midday: Levi Strauss, Biogen, Micron & moreThese are the stocks posting the largest moves midday Thursday.
Weiterlesen »
Here are the biggest analyst calls of the day: Biogen, Apple, Micron, & moreHere are the biggest calls on Wall Street on Thursday
Weiterlesen »
Stocks making the biggest moves premarket: Biogen, Boeing, Walmart, Apple, Clorox & moreSome of the names on the move ahead of the open.
Weiterlesen »
Biogen is crashing after scrapping its late-stage Alzheimer's drug trialsBiogen shares crashed more than 25% in pre-market trading after discontinuing two late-stage Alzheimer's drug trials with Eisai.
Weiterlesen »